This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Applied Genetic Technologies Gestion

Gestion contrôle des critères 1/4

Informations clés

Sue Washer

Directeur général

US$1.5m

Rémunération totale

Pourcentage du salaire du PDG	37.4%
Durée du mandat du directeur général	20.8yrs
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	1.5yrs
Durée moyenne du mandat des membres du conseil d'administration	11.4yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Sue Washer a-t-elle évolué par rapport aux bénéfices de Applied Genetic Technologies?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2022	n/a	n/a	-US$70m
Jun 30 2022	US$1m	US$551k	-US$69m
Mar 31 2022	n/a	n/a	-US$63m
Dec 31 2021	n/a	n/a	-US$63m
Sep 30 2021	n/a	n/a	-US$60m
Jun 30 2021	US$1m	US$530k	-US$58m
Mar 31 2021	n/a	n/a	-US$60m
Dec 31 2020	n/a	n/a	-US$57m
Sep 30 2020	n/a	n/a	-US$50m
Jun 30 2020	US$988k	US$530k	-US$46m
Mar 31 2020	n/a	n/a	-US$42m
Dec 31 2019	n/a	n/a	-US$19m
Sep 30 2019	n/a	n/a	-US$15m
Jun 30 2019	US$1m	US$514k	-US$2m
Mar 31 2019	n/a	n/a	US$2m
Dec 31 2018	n/a	n/a	-US$18m
Sep 30 2018	n/a	n/a	-US$19m
Jun 30 2018	US$1m	US$502k	-US$21m
Mar 31 2018	n/a	n/a	-US$18m
Dec 31 2017	n/a	n/a	-US$11m
Sep 30 2017	n/a	n/a	-US$4m
Jun 30 2017	US$1m	US$487k	US$407k
Mar 31 2017	n/a	n/a	US$6m
Dec 31 2016	n/a	n/a	US$10m
Sep 30 2016	n/a	n/a	US$11m
Jun 30 2016	US$2m	US$464k	-US$1m

Rémunération vs marché: Sue's total compensation ($USD1.47M) is above average for companies of similar size in the German market ($USD429.60K).

Rémunération et revenus: Sue's compensation has increased whilst the company is unprofitable.

PDG

Sue Washer (61 yo)

20.8yrs

Titularisation

US$1,473,567

Compensation

Ms. Susan B. Washer, also known as Sue, has been the President and Chief Executive Officer of Applied Genetic Technologies Corporation since March 2002. Ms. Washer is an experienced entrepreneur with a str...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Susan Washer	President	20.8yrs	US$1.47m	pas de données
Jonathan Lieber	Chief Financial Officer	1.3yrs	US$1.00m	pas de données
Susan Schneider	Chief Medical Officer	1.1yrs	US$832.63k	pas de données
Nicholas Muzyczka	Co-Founder	23.9yrs	pas de données	pas de données
Barry Byrne	Co-Founder	23.9yrs	pas de données	pas de données
William Hauswirth	Co-Founder & Member of Ophthalmology Scientific Advisory Board	no data	pas de données	pas de données
Richard Samulski	Co-Founder	23.9yrs	pas de données	pas de données
Terence Flotte	Co-Founder	23.9yrs	pas de données	pas de données
Gerald Reynolds	Chief Accounting Officer	1.5yrs	pas de données	0% € 0
Abraham Scaria	Chief Scientific Officer	less than a year	pas de données	pas de données
Hope D'Oyley-Gay	General Counsel	less than a year	pas de données	pas de données
David Knop	Senior Vice President of Process & Assay Development	less than a year	US$141.25k	pas de données

1.5yrs

Durée moyenne de l'emploi

57yo

Âge moyen

Gestion expérimentée: 2GT's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Susan Washer	President	19.1yrs	US$1.47m	pas de données
William Hauswirth	Co-Founder & Member of Ophthalmology Scientific Advisory Board	no data	pas de données	pas de données
Edward Hurwitz	Independent Director	10.1yrs	US$65.23k	0% € 0
Anne VanLent	Independent Director	6.3yrs	US$79.23k	pas de données
Scott Koenig	Independent Chairman of the Board	20.7yrs	US$101.50k	0% € 0
David Birch	Member of Ophthalmology Scientific Advisory Board	no data	pas de données	pas de données
William Aliski	Independent Director	4.3yrs	US$78.23k	0% € 0
Peter Campochiaro	Member of Ophthalmology Scientific Advisory Board	no data	pas de données	pas de données
James Rosen	Independent Director	12.8yrs	US$72.34k	0% € 0
Paul Kaufman	Member of Ophthalmology Scientific Advisory Board	no data	pas de données	pas de données
Stephen Daiger	Member of Ophthalmology Scientific Advisory Board	no data	pas de données	pas de données
Robert Molday	Member of Ophthalmology Scientific Advisory Board	no data	pas de données	pas de données

11.4yrs

Durée moyenne de l'emploi

65.5yo

Âge moyen

Conseil d'administration expérimenté: 2GT's board of directors are seasoned and experienced ( 11.4 years average tenure).

This company listing is no longer active

Applied Genetic Technologies Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

Insufficient new directors

Applied Genetic Technologies Corporation Announces Executive Appointments

Insufficient new directors

Insufficient new directors

Ivana Magovcevic-Liebisch Resigns from Board of Directors and Each Committee of Which She Was A Member of Applied Genetic Technologies Corporation, Effective March 9, 2022

Insufficient new directors

Recent updates

Applied Genetic Technologies Corporation(NasdaqGM:AGTC) dropped from NASDAQ Composite Index

Syncona Limited (LSE:SYNC), a fund managed by Syncona Investment Management Limited completed the acquisition of Applied Genetic Technologies Corporation (NasdaqGM:AGTC).

Applied Genetic Technologies Corporation announced delayed 10-Q filing

Insufficient new directors

Syncona Limited (LSE:SYNC), a fund managed by Syncona Investment Management Limited, entered into a definitive agreement to acquire Applied Genetic Technologies Corporation (NasdaqGM:AGTC) for $23.3 million.

Applied Genetic Technologies Corporation has completed a Follow-on Equity Offering.

Applied Genetic Technologies Corporation has completed a Follow-on Equity Offering.

Applied Genetic Technologies Receives Non-Compliance Notice from Nasdaq

Applied Genetic Technologies Corporation Announces Executive Appointments

AGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa

Applied Genetic Technologies Corporation Presents Positive 18-Month Data from Ongoing Phase 1/2 Clinical Study of AGTC-501 At the Association for Research in Vision and Ophthalmology 2022 Annual Meeting

Insufficient new directors

Insufficient new directors

Ivana Magovcevic-Liebisch Resigns from Board of Directors and Each Committee of Which She Was A Member of Applied Genetic Technologies Corporation, Effective March 9, 2022

Insufficient new directors

Applied Genetic Technologies Reports Updated Interim Three-Month Pediatric Results and Additional Adult Safety Results Out to as Long as 24 Months from Its Ongoing Phase 1/2 Dose Escalation Study of AGTC-401

Applied Genetic Technologies Corporation to Report Q2, 2022 Results on Feb 14, 2022

AGTC Exceeds Enrollment Target in SKYLINE Trial of AGTC-501 for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

Insufficient new directors

Insufficient new directors

Applied Genetic Technologies Corporation Announces Ongoing Clinical Trials in achromatopsia and X-Linked Retinitis Pigmentosa at the Fourteenth International Symposium on Retinal Degeneration

Applied Genetic Technologies Corporation(NasdaqGM:AGTC) dropped from Russell 3000E Index

Applied Genetic Technologies Corporation Reports 12-Month Data from Its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients with Mutations in the ACHM B3 Gene

Otonomy, Inc. and Applied Genetic Technologies Corporation Present Preclinical Proof-Of-Concept Results for Oto-825 Gene Therapy At ASGCT Annual Meeting

Applied Genetic Technologies Corporation Advances for Manufacturing its XLRP Gene Therapy Candidate in Two Abstracts at ASGCT

Applied Genetic Technologies Corporation Reports Additional Positive Data from the Ongoing X-Linked Retinitis Pigmentosa Phase 1/2 Clinical Trial

Agtc Clinical Investigators Provide Encore Presentation of Data from the Company’s Ongoing XLRP and Achromatopsia Phase 1/2 Trials

Revenue in line with expectations

Applied Genetic Technologies Corporation to Report Q2, 2021 Results on Feb 11, 2021

New 90-day low: €3.20

Applied Genetic Technologies Corporation has completed a Follow-on Equity Offering in the amount of $74.5 million.

New 90-day low: €3.30

New 90-day low: €3.94

Revenue in line with expectations

Applied Genetic Technologies Corporation Reports Additional Positive Data from its Phase 1/2 Clinical Trial in Patients with X-Linked Retinitis Pigmentosa

Applied Genetic Technologies Corporation Plans to Release 12-Month Data for Groups 1 Through 4 Evaluating Durability of Effect and Continued Safety and Interim Data of Groups 5 and 6 Evaluating Safety and Efficacy at Higher Doses for its Phase 1/2 Clinical Trial

Applied Genetic Technologies Corporation, Annual General Meeting, Dec 16, 2020

Applied Genetic Technologies Corporation Joins the My Retina Tracker® Program as A New Scientific Collaborator

New 90-day low: €4.14

Full year earnings released - €2.17 loss per share

Applied Genetic Technologies Corporation to Report Q4, 2020 Results on Sep 09, 2020

New 90-day low - €4.16

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen